• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过多种吸血生物唾液肽的杂交设计超强效三价抗凝剂。

Engineering ultrapotent trivalent anticoagulants through hybridisation of salivary peptides from multiple haematophagous organisms.

作者信息

Maxwell Joshua W C, Ripoll-Rozada Jorge, Mackay Angus S, Alwis Imala, Ford Daniel J, Trought Cameron B J, Santos Joana A, Smythe Rhyll E, Liu Joanna S T, Zuccolotto Zack, Schoenwaelder Simone M, Jackson Shaun P, Pereira Pedro José Barbosa, Payne Richard J

机构信息

School of Chemistry, Faculty of Science, The University of Sydney NSW Australia

Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Sydney Sydney NSW 2006 Australia.

出版信息

Chem Sci. 2025 Sep 1. doi: 10.1039/d5sc04734j.

DOI:10.1039/d5sc04734j
PMID:40959396
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12434495/
Abstract

Haematophagous organisms are a rich source of salivary anticoagulant polypeptides that exert their activity by blocking the catalytic site and one of two positively charged exosites on the host protease thrombin. Here, we describe a molecular engineering approach to hybridise post-translationally sulfated polypeptides from different blood-feeding organisms to enhance anticoagulant activity. This led to the discovery of a triply sulfated hybrid anticoagulant, XChimera, possessing fragments from flea, leech, and fly salivary polypeptides that exhibits femtomolar inhibitory activity against thrombin. The crystallographic structure of a complex of XChimera with thrombin shows that it displays a trivalent binding mode in which it simultaneously blocks three functional sites of the protease, the active site and exosites I and II. This trivalent chimera exhibited ultrapotent anticoagulant activity in a suite of clotting assays and was also shown to possess potent antithrombotic activity in a murine model of thrombosis.

摘要

吸血生物是唾液抗凝多肽的丰富来源,这些多肽通过阻断宿主蛋白酶凝血酶的催化位点和两个带正电荷的外位点之一来发挥其活性。在此,我们描述了一种分子工程方法,用于将来自不同吸血生物的翻译后硫酸化多肽进行杂交,以增强抗凝活性。这导致发现了一种三重硫酸化的杂交抗凝剂XChimera,它具有来自跳蚤、水蛭和苍蝇唾液多肽的片段,对凝血酶表现出飞摩尔级的抑制活性。XChimera与凝血酶复合物的晶体结构表明,它呈现出一种三价结合模式,即同时阻断蛋白酶的三个功能位点,即活性位点以及外位点I和II。这种三价嵌合体在一系列凝血试验中表现出超强的抗凝活性,并且在血栓形成的小鼠模型中也显示出强大的抗血栓活性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b875/12434495/7b8f2c0a397a/d5sc04734j-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b875/12434495/db0df57f005b/d5sc04734j-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b875/12434495/37396f7787cd/d5sc04734j-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b875/12434495/c401ec343bc7/d5sc04734j-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b875/12434495/53253f3a90de/d5sc04734j-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b875/12434495/7b8f2c0a397a/d5sc04734j-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b875/12434495/db0df57f005b/d5sc04734j-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b875/12434495/37396f7787cd/d5sc04734j-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b875/12434495/c401ec343bc7/d5sc04734j-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b875/12434495/53253f3a90de/d5sc04734j-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b875/12434495/7b8f2c0a397a/d5sc04734j-f5.jpg

相似文献

1
Engineering ultrapotent trivalent anticoagulants through hybridisation of salivary peptides from multiple haematophagous organisms.通过多种吸血生物唾液肽的杂交设计超强效三价抗凝剂。
Chem Sci. 2025 Sep 1. doi: 10.1039/d5sc04734j.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
3
Aspects of Genetic Diversity, Host Specificity and Public Health Significance of Single-Celled Intestinal Parasites Commonly Observed in Humans and Mostly Referred to as 'Non-Pathogenic'.人类常见且大多被称为“非致病性”的单细胞肠道寄生虫的遗传多样性、宿主特异性及公共卫生意义
APMIS. 2025 Sep;133(9):e70036. doi: 10.1111/apm.70036.
4
Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies.抗血小板和抗凝药物用于抗磷脂抗体个体血栓形成的一级预防。
Cochrane Database Syst Rev. 2018 Jul 13;7(7):CD012534. doi: 10.1002/14651858.CD012534.pub2.
5
Management of urinary stones by experts in stone disease (ESD 2025).结石病专家对尿路结石的管理(2025年结石病专家共识)
Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085.
6
Exploiting Chemical Protein Synthesis to Study the Role of Tyrosine Sulfation on Anticoagulants from Hematophagous Organisms.利用化学蛋白质合成研究食血生物抗凝剂中天冬氨酸磺酸化的作用。
Acc Chem Res. 2023 Oct 3;56(19):2688-2699. doi: 10.1021/acs.accounts.3c00388. Epub 2023 Sep 14.
7
Stopping anticoagulation for isolated or incidental pulmonary embolism: the STOPAPE RCT protocol.孤立性或偶发性肺栓塞抗凝治疗的停用:STOPAPE随机对照试验方案
Health Technol Assess. 2024 Jun;29(11):1-17. doi: 10.3310/HRCW7937.
8
Electrophoresis电泳
9
Dabigatran Attenuates the Binding of Thrombin to Platelets-A Novel Mechanism of Action.达比加群可减弱凝血酶与血小板的结合——一种新的作用机制。
Thromb Haemost. 2025 Aug;125(8):747-756. doi: 10.1055/a-2483-0107. Epub 2024 Nov 25.
10
Pentasaccharides for the prevention of venous thromboembolism.用于预防静脉血栓栓塞的五糖
Cochrane Database Syst Rev. 2016 Oct 31;10(10):CD005134. doi: 10.1002/14651858.CD005134.pub3.

本文引用的文献

1
Development of supramolecular anticoagulants with on-demand reversibility.具有按需可逆性的超分子抗凝剂的研发。
Nat Biotechnol. 2025 Feb;43(2):186-193. doi: 10.1038/s41587-024-02209-z. Epub 2024 Apr 30.
2
Exploiting Chemical Protein Synthesis to Study the Role of Tyrosine Sulfation on Anticoagulants from Hematophagous Organisms.利用化学蛋白质合成研究食血生物抗凝剂中天冬氨酸磺酸化的作用。
Acc Chem Res. 2023 Oct 3;56(19):2688-2699. doi: 10.1021/acs.accounts.3c00388. Epub 2023 Sep 14.
3
Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality.
全球可改变风险因素对心血管疾病和死亡的影响。
N Engl J Med. 2023 Oct 5;389(14):1273-1285. doi: 10.1056/NEJMoa2206916. Epub 2023 Aug 26.
4
Therapeutic peptides: current applications and future directions.治疗性肽:当前的应用及未来方向。
Signal Transduct Target Ther. 2022 Feb 14;7(1):48. doi: 10.1038/s41392-022-00904-4.
5
Global Epidemiology of Stroke and Access to Acute Ischemic Stroke Interventions.全球卒中流行病学和急性缺血性卒中干预措施的可及性。
Neurology. 2021 Nov 16;97(20 Suppl 2):S6-S16. doi: 10.1212/WNL.0000000000012781.
6
Identification of a substrate-like cleavage-resistant thrombin inhibitor from the saliva of the flea Xenopsylla cheopis.从印鼠客蚤唾液中鉴定出一种类底物切割抗性的凝血酶抑制剂。
J Biol Chem. 2021 Nov;297(5):101322. doi: 10.1016/j.jbc.2021.101322. Epub 2021 Oct 21.
7
Synthesis and evaluation of peptidic thrombin inhibitors bearing acid-stable sulfotyrosine analogues.含酸稳定磺酪氨酸类似物的肽类凝血酶抑制剂的合成与评价。
Chem Commun (Camb). 2021 Oct 19;57(83):10923-10926. doi: 10.1039/d1cc04742f.
8
Epidemiology of cardiovascular disease in Europe.欧洲心血管疾病的流行病学。
Nat Rev Cardiol. 2022 Feb;19(2):133-143. doi: 10.1038/s41569-021-00607-3. Epub 2021 Sep 8.
9
Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.1990—2019年全球、区域和国家的卒中负担及其风险因素:全球疾病负担研究2019的系统分析
Lancet Neurol. 2021 Oct;20(10):795-820. doi: 10.1016/S1474-4422(21)00252-0. Epub 2021 Sep 3.
10
The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030.柳叶刀妇女与心血管疾病委员会:到 2030 年降低全球负担。
Lancet. 2021 Jun 19;397(10292):2385-2438. doi: 10.1016/S0140-6736(21)00684-X. Epub 2021 May 16.